MPG.eBooks - Search Results

1

Ultra orphan drugs : London, November 2004

Published 2004

National Institute for Clinical Excellence (Great Britain)

Subjects: “...Drug Costs / standards...”

Read Now

2

Ultra orphan drugs : London, November 2004

Published 2004

National Institute for Clinical Excellence (Great Britain)

Subjects: “...Drug Costs / standards...”

Read Now

3

Saving lives, buying time : economics of malaria drugs in an age of resistance

by Arrow, Kenneth J.
Published 2004

The National Academies Press

Subjects: “...Drug Costs...”

Read Now

4

Making medicines affordable : a national imperative

Published 2017

National Academies Press

Subjects: “...Drug Costs...”

Read Now

5

Ensuring access to medicines : how to redesign pricing, reimbursement and procurement?

by Vogler, Sabine, Paris, Valérie, Panteli, Dimitra
Published 2018

World Health Organization, Regional Office for Europe

Subjects: “...Drug Costs...”

Read Now

6

CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

7

CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

8

CADTH Canadian Drug Expert Committee recommendation: Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemi...

Published 2018

CADTH

Subjects: “...Drug Costs...”

Read Now

9

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

10

CADTH Canadian Drug Expert Committee final recommendation: Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

11

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

12

CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

13

CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

14

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Drug Costs...”

Read Now

15

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

16

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Drug Costs...”

Read Now

17

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

18

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

19

CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary ty...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

20

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Narrow Search